Zydelig is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat relapsed cases of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular B-cell non-Hodgkin lymphoma. Zydelig is used in cases where other therapies have already been tried. In cases of CLL, Zydelig is combined with Rituxan. Zydelig is also referred to by its drug name, idelalisib.
Zydelig is used as targeted therapy for leukemia. Zydelig is a member of a class of drugs called kinase inhibitors. Zydelig is believed to work by triggering cell death in leukemia cells.
How do I take it?
Prescribing information states that Zydelig is taken orally twice daily.
Zydelig comes in the form of a tablet.
The FDA-approved label for Zydelig lists common side effects including fever, fatigue, cough, rash, nausea, abdominal pain, fetal harm, and pneumonia. Severe infections, diarrhea, intestinal inflammation, and liver damage are common and potentially life-threatening side effects in those who take Zydelig.
Rare but serious side effects listed for Zydelig include intestinal perforations and lung inflammation.
For more details about this treatment, visit:
Zydelig — Gilead
CLL: Chemotherapy and Drug Therapy — Leukemia & Lymphoma Society